 | • レポートコード：QYR2104Z4911 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、95ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、放射免疫療法のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（非ホジキンリンパ腫（NHL）、濾胞性リンパ腫、固形腫瘍、乳がん、卵巣がん、骨肉腫、神経芽細胞腫、前立腺がん）、用途別市場規模（腫瘍抗原、放射性核種、抗体）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・放射免疫療法の市場動向 ・企業の競争状況、市場シェア ・放射免疫療法の種類別市場規模（非ホジキンリンパ腫（NHL）、濾胞性リンパ腫、固形腫瘍、乳がん、卵巣がん、骨肉腫、神経芽細胞腫、前立腺がん） ・放射免疫療法の用途別市場規模（腫瘍抗原、放射性核種、抗体） ・放射免疫療法の北米市場規模2016-2027（アメリカ、カナダ） ・放射免疫療法のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・放射免疫療法のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・放射免疫療法の中南米市場規模2016-2027（メキシコ、ブラジル） ・放射免疫療法の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Bayer Healthcare Pharmaceuticals、BioSynthema、Clarity Pharmaceuticals、Curasight、Endocyte、Immunomedics、Molecular Insight Pharmaceuticals、Nordic Nanovector、PDL Biopharma、Philogen、RadioMedix、Stella Pharma、Telix Pharmaceuticals） ・結論 |
Market Analysis and Insights: Global Radioimmunotherapy Market
The global Radioimmunotherapy market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Radioimmunotherapy market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Radioimmunotherapy market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Radioimmunotherapy market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Radioimmunotherapy market.
Global Radioimmunotherapy Scope and Market Size
Radioimmunotherapy market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Radioimmunotherapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Non Hodgkin Lymphoma (NHL)
Follicular Lymphoma
Solid Tumors
Breast Cancer
Ovarian Cancer
Osteosarcoma
Neuroblastoma
Prostate Cancer
Segment by Application
Tumor Antigens
Radionuclides
Antibodies
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Bayer Healthcare Pharmaceuticals
BioSynthema
Clarity Pharmaceuticals
Curasight
Endocyte
Immunomedics
Molecular Insight Pharmaceuticals
Nordic Nanovector
PDL Biopharma
Curasight
Endocyte
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Radioimmunotherapy Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Non Hodgkin Lymphoma (NHL)
1.2.3 Follicular Lymphoma
1.2.4 Solid Tumors
1.2.5 Breast Cancer
1.2.6 Ovarian Cancer
1.2.7 Osteosarcoma
1.2.8 Neuroblastoma
1.2.9 Prostate Cancer
1.3 Market by Application
1.3.1 Global Radioimmunotherapy Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Tumor Antigens
1.3.3 Radionuclides
1.3.4 Antibodies
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Radioimmunotherapy Market Perspective (2016-2027)
2.2 Radioimmunotherapy Growth Trends by Regions
2.2.1 Radioimmunotherapy Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Radioimmunotherapy Historic Market Share by Regions (2016-2021)
2.2.3 Radioimmunotherapy Forecasted Market Size by Regions (2022-2027)
2.3 Radioimmunotherapy Industry Dynamic
2.3.1 Radioimmunotherapy Market Trends
2.3.2 Radioimmunotherapy Market Drivers
2.3.3 Radioimmunotherapy Market Challenges
2.3.4 Radioimmunotherapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Radioimmunotherapy Players by Revenue
3.1.1 Global Top Radioimmunotherapy Players by Revenue (2016-2021)
3.1.2 Global Radioimmunotherapy Revenue Market Share by Players (2016-2021)
3.2 Global Radioimmunotherapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Radioimmunotherapy Revenue
3.4 Global Radioimmunotherapy Market Concentration Ratio
3.4.1 Global Radioimmunotherapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Radioimmunotherapy Revenue in 2020
3.5 Radioimmunotherapy Key Players Head office and Area Served
3.6 Key Players Radioimmunotherapy Product Solution and Service
3.7 Date of Enter into Radioimmunotherapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Radioimmunotherapy Breakdown Data by Type
4.1 Global Radioimmunotherapy Historic Market Size by Type (2016-2021)
4.2 Global Radioimmunotherapy Forecasted Market Size by Type (2022-2027)
5 Radioimmunotherapy Breakdown Data by Application
5.1 Global Radioimmunotherapy Historic Market Size by Application (2016-2021)
5.2 Global Radioimmunotherapy Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Radioimmunotherapy Market Size (2016-2027)
6.2 North America Radioimmunotherapy Market Size by Type
6.2.1 North America Radioimmunotherapy Market Size by Type (2016-2021)
6.2.2 North America Radioimmunotherapy Market Size by Type (2022-2027)
6.2.3 North America Radioimmunotherapy Market Size by Type (2016-2027)
6.3 North America Radioimmunotherapy Market Size by Application
6.3.1 North America Radioimmunotherapy Market Size by Application (2016-2021)
6.3.2 North America Radioimmunotherapy Market Size by Application (2022-2027)
6.3.3 North America Radioimmunotherapy Market Size by Application (2016-2027)
6.4 North America Radioimmunotherapy Market Size by Country
6.4.1 North America Radioimmunotherapy Market Size by Country (2016-2021)
6.4.2 North America Radioimmunotherapy Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Radioimmunotherapy Market Size (2016-2027)
7.2 Europe Radioimmunotherapy Market Size by Type
7.2.1 Europe Radioimmunotherapy Market Size by Type (2016-2021)
7.2.2 Europe Radioimmunotherapy Market Size by Type (2022-2027)
7.2.3 Europe Radioimmunotherapy Market Size by Type (2016-2027)
7.3 Europe Radioimmunotherapy Market Size by Application
7.3.1 Europe Radioimmunotherapy Market Size by Application (2016-2021)
7.3.2 Europe Radioimmunotherapy Market Size by Application (2022-2027)
7.3.3 Europe Radioimmunotherapy Market Size by Application (2016-2027)
7.4 Europe Radioimmunotherapy Market Size by Country
7.4.1 Europe Radioimmunotherapy Market Size by Country (2016-2021)
7.4.2 Europe Radioimmunotherapy Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Radioimmunotherapy Market Size (2016-2027)
8.2 Asia-Pacific Radioimmunotherapy Market Size by Type
8.2.1 Asia-Pacific Radioimmunotherapy Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Radioimmunotherapy Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Radioimmunotherapy Market Size by Type (2016-2027)
8.3 Asia-Pacific Radioimmunotherapy Market Size by Application
8.3.1 Asia-Pacific Radioimmunotherapy Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Radioimmunotherapy Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Radioimmunotherapy Market Size by Application (2016-2027)
8.4 Asia-Pacific Radioimmunotherapy Market Size by Region
8.4.1 Asia-Pacific Radioimmunotherapy Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Radioimmunotherapy Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Radioimmunotherapy Market Size (2016-2027)
9.2 Latin America Radioimmunotherapy Market Size by Type
9.2.1 Latin America Radioimmunotherapy Market Size by Type (2016-2021)
9.2.2 Latin America Radioimmunotherapy Market Size by Type (2022-2027)
9.2.3 Latin America Radioimmunotherapy Market Size by Type (2016-2027)
9.3 Latin America Radioimmunotherapy Market Size by Application
9.3.1 Latin America Radioimmunotherapy Market Size by Application (2016-2021)
9.3.2 Latin America Radioimmunotherapy Market Size by Application (2022-2027)
9.3.3 Latin America Radioimmunotherapy Market Size by Application (2016-2027)
9.4 Latin America Radioimmunotherapy Market Size by Country
9.4.1 Latin America Radioimmunotherapy Market Size by Country (2016-2021)
9.4.2 Latin America Radioimmunotherapy Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Radioimmunotherapy Market Size (2016-2027)
10.2 Middle East & Africa Radioimmunotherapy Market Size by Type
10.2.1 Middle East & Africa Radioimmunotherapy Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Radioimmunotherapy Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Radioimmunotherapy Market Size by Type (2016-2027)
10.3 Middle East & Africa Radioimmunotherapy Market Size by Application
10.3.1 Middle East & Africa Radioimmunotherapy Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Radioimmunotherapy Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Radioimmunotherapy Market Size by Application (2016-2027)
10.4 Middle East & Africa Radioimmunotherapy Market Size by Country
10.4.1 Middle East & Africa Radioimmunotherapy Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Radioimmunotherapy Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Bayer Healthcare Pharmaceuticals
11.1.1 Bayer Healthcare Pharmaceuticals Company Details
11.1.2 Bayer Healthcare Pharmaceuticals Business Overview
11.1.3 Bayer Healthcare Pharmaceuticals Radioimmunotherapy Introduction
11.1.4 Bayer Healthcare Pharmaceuticals Revenue in Radioimmunotherapy Business (2016-2021)
11.1.5 Bayer Healthcare Pharmaceuticals Recent Development
11.2 BioSynthema
11.2.1 BioSynthema Company Details
11.2.2 BioSynthema Business Overview
11.2.3 BioSynthema Radioimmunotherapy Introduction
11.2.4 BioSynthema Revenue in Radioimmunotherapy Business (2016-2021)
11.2.5 BioSynthema Recent Development
11.3 Clarity Pharmaceuticals
11.3.1 Clarity Pharmaceuticals Company Details
11.3.2 Clarity Pharmaceuticals Business Overview
11.3.3 Clarity Pharmaceuticals Radioimmunotherapy Introduction
11.3.4 Clarity Pharmaceuticals Revenue in Radioimmunotherapy Business (2016-2021)
11.3.5 Clarity Pharmaceuticals Recent Development
11.4 Curasight
11.4.1 Curasight Company Details
11.4.2 Curasight Business Overview
11.4.3 Curasight Radioimmunotherapy Introduction
11.4.4 Curasight Revenue in Radioimmunotherapy Business (2016-2021)
11.4.5 Curasight Recent Development
11.5 Endocyte
11.5.1 Endocyte Company Details
11.5.2 Endocyte Business Overview
11.5.3 Endocyte Radioimmunotherapy Introduction
11.5.4 Endocyte Revenue in Radioimmunotherapy Business (2016-2021)
11.5.5 Endocyte Recent Development
11.6 Immunomedics
11.6.1 Immunomedics Company Details
11.6.2 Immunomedics Business Overview
11.6.3 Immunomedics Radioimmunotherapy Introduction
11.6.4 Immunomedics Revenue in Radioimmunotherapy Business (2016-2021)
11.6.5 Immunomedics Recent Development
11.7 Molecular Insight Pharmaceuticals
11.7.1 Molecular Insight Pharmaceuticals Company Details
11.7.2 Molecular Insight Pharmaceuticals Business Overview
11.7.3 Molecular Insight Pharmaceuticals Radioimmunotherapy Introduction
11.7.4 Molecular Insight Pharmaceuticals Revenue in Radioimmunotherapy Business (2016-2021)
11.7.5 Molecular Insight Pharmaceuticals Recent Development
11.8 Nordic Nanovector
11.8.1 Nordic Nanovector Company Details
11.8.2 Nordic Nanovector Business Overview
11.8.3 Nordic Nanovector Radioimmunotherapy Introduction
11.8.4 Nordic Nanovector Revenue in Radioimmunotherapy Business (2016-2021)
11.8.5 Nordic Nanovector Recent Development
11.9 PDL Biopharma
11.9.1 PDL Biopharma Company Details
11.9.2 PDL Biopharma Business Overview
11.9.3 PDL Biopharma Radioimmunotherapy Introduction
11.9.4 PDL Biopharma Revenue in Radioimmunotherapy Business (2016-2021)
11.9.5 PDL Biopharma Recent Development
11.10 Philogen
11.10.1 Philogen Company Details
11.10.2 Philogen Business Overview
11.10.3 Philogen Radioimmunotherapy Introduction
11.10.4 Philogen Revenue in Radioimmunotherapy Business (2016-2021)
11.10.5 Philogen Recent Development
11.11 RadioMedix
11.11.1 RadioMedix Company Details
11.11.2 RadioMedix Business Overview
11.11.3 RadioMedix Radioimmunotherapy Introduction
11.11.4 RadioMedix Revenue in Radioimmunotherapy Business (2016-2021)
11.11.5 RadioMedix Recent Development
11.12 Stella Pharma
11.12.1 Stella Pharma Company Details
11.12.2 Stella Pharma Business Overview
11.12.3 Stella Pharma Radioimmunotherapy Introduction
11.12.4 Stella Pharma Revenue in Radioimmunotherapy Business (2016-2021)
11.12.5 Stella Pharma Recent Development
11.13 Telix Pharmaceuticals
11.13.1 Telix Pharmaceuticals Company Details
11.13.2 Telix Pharmaceuticals Business Overview
11.13.3 Telix Pharmaceuticals Radioimmunotherapy Introduction
11.13.4 Telix Pharmaceuticals Revenue in Radioimmunotherapy Business (2016-2021)
11.13.5 Telix Pharmaceuticals Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Radioimmunotherapy Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Non Hodgkin Lymphoma (NHL)
Table 3. Key Players of Follicular Lymphoma
Table 4. Key Players of Solid Tumors
Table 5. Key Players of Breast Cancer
Table 6. Key Players of Ovarian Cancer
Table 7. Key Players of Osteosarcoma
Table 8. Key Players of Neuroblastoma
Table 9. Key Players of Prostate Cancer
Table 10. Global Radioimmunotherapy Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 11. Global Radioimmunotherapy Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 12. Global Radioimmunotherapy Market Size by Regions (2016-2021) & (US$ Million)
Table 13. Global Radioimmunotherapy Market Share by Regions (2016-2021)
Table 14. Global Radioimmunotherapy Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 15. Global Radioimmunotherapy Market Share by Regions (2022-2027)
Table 16. Radioimmunotherapy Market Trends
Table 17. Radioimmunotherapy Market Drivers
Table 18. Radioimmunotherapy Market Challenges
Table 19. Radioimmunotherapy Market Restraints
Table 20. Global Radioimmunotherapy Revenue by Players (2016-2021) & (US$ Million)
Table 21. Global Radioimmunotherapy Market Share by Players (2016-2021)
Table 22. Global Top Radioimmunotherapy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Radioimmunotherapy as of 2020)
Table 23. Ranking of Global Top Radioimmunotherapy Companies by Revenue (US$ Million) in 2020
Table 24. Global 5 Largest Players Market Share by Radioimmunotherapy Revenue (CR5 and HHI) & (2016-2021)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Radioimmunotherapy Product Solution and Service
Table 27. Date of Enter into Radioimmunotherapy Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Radioimmunotherapy Market Size by Type (2016-2021) (US$ Million)
Table 30. Global Radioimmunotherapy Revenue Market Share by Type (2016-2021)
Table 31. Global Radioimmunotherapy Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 32. Global Radioimmunotherapy Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 33. Global Radioimmunotherapy Market Size Share by Application (2016-2021) & (US$ Million)
Table 34. Global Radioimmunotherapy Revenue Market Share by Application (2016-2021)
Table 35. Global Radioimmunotherapy Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 36. Global Radioimmunotherapy Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 37. North America Radioimmunotherapy Market Size by Type (2016-2021) (US$ Million)
Table 38. North America Radioimmunotherapy Market Size by Type (2022-2027) & (US$ Million)
Table 39. North America Radioimmunotherapy Market Size by Application (2016-2021) (US$ Million)
Table 40. North America Radioimmunotherapy Market Size by Application (2022-2027) & (US$ Million)
Table 41. North America Radioimmunotherapy Market Size by Country (2016-2021) & (US$ Million)
Table 42. North America Radioimmunotherapy Market Size by Country (2022-2027) & (US$ Million)
Table 43. Europe Radioimmunotherapy Market Size by Type (2016-2021) (US$ Million)
Table 44. Europe Radioimmunotherapy Market Size by Type (2022-2027) & (US$ Million)
Table 45. Europe Radioimmunotherapy Market Size by Application (2016-2021) (US$ Million)
Table 46. Europe Radioimmunotherapy Market Size by Application (2022-2027) & (US$ Million)
Table 47. Europe Radioimmunotherapy Market Size by Country (2016-2021) & (US$ Million)
Table 48. Europe Radioimmunotherapy Market Size by Country (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Radioimmunotherapy Market Size by Type (2016-2021) (US$ Million)
Table 50. Asia-Pacific Radioimmunotherapy Market Size by Type (2022-2027) & (US$ Million)
Table 51. Asia-Pacific Radioimmunotherapy Market Size by Application (2016-2021) (US$ Million)
Table 52. Asia-Pacific Radioimmunotherapy Market Size by Application (2022-2027) & (US$ Million)
Table 53. Asia-Pacific Radioimmunotherapy Market Size by Region (2016-2021) & (US$ Million)
Table 54. Asia-Pacific Radioimmunotherapy Market Size by Region (2022-2027) & (US$ Million)
Table 55. Latin America Radioimmunotherapy Market Size by Type (2016-2021) (US$ Million)
Table 56. Latin America Radioimmunotherapy Market Size by Type (2022-2027) & (US$ Million)
Table 57. Latin America Radioimmunotherapy Market Size by Application (2016-2021) (US$ Million)
Table 58. Latin America Radioimmunotherapy Market Size by Application (2022-2027) & (US$ Million)
Table 59. Latin America Radioimmunotherapy Market Size by Country (2016-2021) & (US$ Million)
Table 60. Latin America Radioimmunotherapy Market Size by Country (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Radioimmunotherapy Market Size by Type (2016-2021) (US$ Million)
Table 62. Middle East & Africa Radioimmunotherapy Market Size by Type (2022-2027) & (US$ Million)
Table 63. Middle East & Africa Radioimmunotherapy Market Size by Application (2016-2021) (US$ Million)
Table 64. Middle East & Africa Radioimmunotherapy Market Size by Application (2022-2027) & (US$ Million)
Table 65. Middle East & Africa Radioimmunotherapy Market Size by Country (2016-2021) & (US$ Million)
Table 66. Middle East & Africa Radioimmunotherapy Market Size by Country (2022-2027) & (US$ Million)
Table 67. Bayer Healthcare Pharmaceuticals Company Details
Table 68. Bayer Healthcare Pharmaceuticals Business Overview
Table 69. Bayer Healthcare Pharmaceuticals Radioimmunotherapy Product
Table 70. Bayer Healthcare Pharmaceuticals Revenue in Radioimmunotherapy Business (2016-2021) & (US$ Million)
Table 71. Bayer Healthcare Pharmaceuticals Recent Development
Table 72. BioSynthema Company Details
Table 73. BioSynthema Business Overview
Table 74. BioSynthema Radioimmunotherapy Product
Table 75. BioSynthema Revenue in Radioimmunotherapy Business (2016-2021) & (US$ Million)
Table 76. BioSynthema Recent Development
Table 77. Clarity Pharmaceuticals Company Details
Table 78. Clarity Pharmaceuticals Business Overview
Table 79. Clarity Pharmaceuticals Radioimmunotherapy Product
Table 80. Clarity Pharmaceuticals Revenue in Radioimmunotherapy Business (2016-2021) & (US$ Million)
Table 81. Clarity Pharmaceuticals Recent Development
Table 82. Curasight Company Details
Table 83. Curasight Business Overview
Table 84. Curasight Radioimmunotherapy Product
Table 85. Curasight Revenue in Radioimmunotherapy Business (2016-2021) & (US$ Million)
Table 86. Curasight Recent Development
Table 87. Endocyte Company Details
Table 88. Endocyte Business Overview
Table 89. Endocyte Radioimmunotherapy Product
Table 90. Endocyte Revenue in Radioimmunotherapy Business (2016-2021) & (US$ Million)
Table 91. Endocyte Recent Development
Table 92. Immunomedics Company Details
Table 93. Immunomedics Business Overview
Table 94. Immunomedics Radioimmunotherapy Product
Table 95. Immunomedics Revenue in Radioimmunotherapy Business (2016-2021) & (US$ Million)
Table 96. Immunomedics Recent Development
Table 97. Molecular Insight Pharmaceuticals Company Details
Table 98. Molecular Insight Pharmaceuticals Business Overview
Table 99. Molecular Insight Pharmaceuticals Radioimmunotherapy Product
Table 100. Molecular Insight Pharmaceuticals Revenue in Radioimmunotherapy Business (2016-2021) & (US$ Million)
Table 101. Molecular Insight Pharmaceuticals Recent Development
Table 102. Nordic Nanovector Company Details
Table 103. Nordic Nanovector Business Overview
Table 104. Nordic Nanovector Revenue in Radioimmunotherapy Business (2016-2021) & (US$ Million)
Table 105. Nordic Nanovector Recent Development
Table 106. PDL Biopharma Company Details
Table 107. PDL Biopharma Business Overview
Table 108. PDL Biopharma Radioimmunotherapy Product
Table 109. PDL Biopharma Revenue in Radioimmunotherapy Business (2016-2021) & (US$ Million)
Table 110. PDL Biopharma Recent Development
Table 111. Philogen Company Details
Table 112. Philogen Business Overview
Table 113. Philogen Radioimmunotherapy Product
Table 114. Philogen Revenue in Radioimmunotherapy Business (2016-2021) & (US$ Million)
Table 115. Philogen Recent Development
Table 116. RadioMedix Company Details
Table 117. RadioMedix Business Overview
Table 118. RadioMedix Radioimmunotherapy Product
Table 119. RadioMedix Revenue in Radioimmunotherapy Business (2016-2021) & (US$ Million)
Table 120. RadioMedix Recent Development
Table 121. Stella Pharma Company Details
Table 122. Stella Pharma Business Overview
Table 123. Stella Pharma Radioimmunotherapy Product
Table 124. Stella Pharma Revenue in Radioimmunotherapy Business (2016-2021) & (US$ Million)
Table 125. Stella Pharma Recent Development
Table 126. Telix Pharmaceuticals Company Details
Table 127. Telix Pharmaceuticals Business Overview
Table 128. Telix Pharmaceuticals Radioimmunotherapy Product
Table 129. Telix Pharmaceuticals Revenue in Radioimmunotherapy Business (2016-2021) & (US$ Million)
Table 130. Telix Pharmaceuticals Recent Development
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Radioimmunotherapy Market Share by Type: 2020 VS 2027
Figure 2. Non Hodgkin Lymphoma (NHL) Features
Figure 3. Follicular Lymphoma Features
Figure 4. Solid Tumors Features
Figure 5. Breast Cancer Features
Figure 6. Ovarian Cancer Features
Figure 7. Osteosarcoma Features
Figure 8. Neuroblastoma Features
Figure 9. Prostate Cancer Features
Figure 10. Global Radioimmunotherapy Market Share by Application: 2020 VS 2027
Figure 11. Tumor Antigens Case Studies
Figure 12. Radionuclides Case Studies
Figure 13. Antibodies Case Studies
Figure 14. Radioimmunotherapy Report Years Considered
Figure 15. Global Radioimmunotherapy Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 16. Global Radioimmunotherapy Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 17. Global Radioimmunotherapy Market Share by Regions: 2020 VS 2027
Figure 18. Global Radioimmunotherapy Market Share by Regions (2022-2027)
Figure 19. Global Radioimmunotherapy Market Share by Players in 2020
Figure 20. Global Top Radioimmunotherapy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Radioimmunotherapy as of 2020
Figure 21. The Top 10 and 5 Players Market Share by Radioimmunotherapy Revenue in 2020
Figure 22. Global Radioimmunotherapy Revenue Market Share by Type (2016-2021)
Figure 23. Global Radioimmunotherapy Revenue Market Share by Type (2022-2027)
Figure 24. North America Radioimmunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. North America Radioimmunotherapy Market Share by Type (2016-2027)
Figure 26. North America Radioimmunotherapy Market Share by Application (2016-2027)
Figure 27. North America Radioimmunotherapy Market Share by Country (2016-2027)
Figure 28. United States Radioimmunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Canada Radioimmunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Europe Radioimmunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Europe Radioimmunotherapy Market Share by Type (2016-2027)
Figure 32. Europe Radioimmunotherapy Market Share by Application (2016-2027)
Figure 33. Europe Radioimmunotherapy Market Share by Country (2016-2027)
Figure 34. Germany Radioimmunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. France Radioimmunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. U.K. Radioimmunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Italy Radioimmunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Russia Radioimmunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Nordic Radioimmunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Asia-Pacific Radioimmunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Asia-Pacific Radioimmunotherapy Market Share by Type (2016-2027)
Figure 42. Asia-Pacific Radioimmunotherapy Market Share by Application (2016-2027)
Figure 43. Asia-Pacific Radioimmunotherapy Market Share by Region (2016-2027)
Figure 44. China Radioimmunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Japan Radioimmunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. South Korea Radioimmunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Southeast Asia Radioimmunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. India Radioimmunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Australia Radioimmunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Latin America Radioimmunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Latin America Radioimmunotherapy Market Share by Type (2016-2027)
Figure 52. Latin America Radioimmunotherapy Market Share by Application (2016-2027)
Figure 53. Latin America Radioimmunotherapy Market Share by Country (2016-2027)
Figure 54. Mexico Radioimmunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Brazil Radioimmunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Middle East & Africa Radioimmunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Middle East & Africa Radioimmunotherapy Market Share by Type (2016-2027)
Figure 58. Middle East & Africa Radioimmunotherapy Market Share by Application (2016-2027)
Figure 59. Middle East & Africa Radioimmunotherapy Market Share by Country (2016-2027)
Figure 60. Turkey Radioimmunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. Saudi Arabia Radioimmunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 62. UAE Radioimmunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 63. Bayer Healthcare Pharmaceuticals Revenue Growth Rate in Radioimmunotherapy Business (2016-2021)
Figure 64. BioSynthema Revenue Growth Rate in Radioimmunotherapy Business (2016-2021)
Figure 65. Clarity Pharmaceuticals Revenue Growth Rate in Radioimmunotherapy Business (2016-2021)
Figure 66. Curasight Revenue Growth Rate in Radioimmunotherapy Business (2016-2021)
Figure 67. Endocyte Revenue Growth Rate in Radioimmunotherapy Business (2016-2021)
Figure 68. Immunomedics Revenue Growth Rate in Radioimmunotherapy Business (2016-2021)
Figure 69. Molecular Insight Pharmaceuticals Revenue Growth Rate in Radioimmunotherapy Business (2016-2021)
Figure 70. Nordic Nanovector Revenue Growth Rate in Radioimmunotherapy Business (2016-2021)
Figure 71. PDL Biopharma Revenue Growth Rate in Radioimmunotherapy Business (2016-2021)
Figure 72. Philogen Revenue Growth Rate in Radioimmunotherapy Business (2016-2021)
Figure 73. RadioMedix Revenue Growth Rate in Radioimmunotherapy Business (2016-2021)
Figure 74. Stella Pharma Revenue Growth Rate in Radioimmunotherapy Business (2016-2021)
Figure 75. Telix Pharmaceuticals Revenue Growth Rate in Radioimmunotherapy Business (2016-2021)
Figure 76. Bottom-up and Top-down Approaches for This Report
Figure 77. Data Triangulation
Figure 78. Key Executives Interviewed
世界の濾胞性リンパ腫治療薬市場規模・現状・予測（2021年-2027年） Follicular lymphoma is a type of blood cancer. It is the most common of the indolent (slow-growing) non-Hodgkin's lymphomas, and the second-most-common form of non-Hodgkin's lymphomas overall. It is defined as a lymphoma of follicle center B-cells (centrocytes and centroblasts), which has at least a…- 世界の非ホジキンリンパ腫（NHL）市場規模・現状・予測（2021年-2027年） Non-Hodgkin Lymphoma is the most common lymphoma which affects large number of people. It begins in lymphocytes present in lymph nodes of body parts such as neck or chest or under the arms. It widely spreads to the other lymph nodes and to other organs such as bone marrow, lungs, or liver. Market An…
- 世界のホジキンリンパ腫治療市場規模・現状・予測（2021年-2027年） Hodgkin's Lymphoma (HL) is defined as the cancer of the lymph tissue, which is part of our immune system. The exact etiology of HL is unknown. However, the risk of developing the condition is increased if a person suffers from a medical condition that weakens the immune system. In HL, cells in the l…
- 世界の非ホジキンリンパ腫治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Non-Hodgkin Lymphoma Therapeutics Market The global Non-Hodgkin Lymphoma Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high da…
- 世界の卵巣がん遺伝子治療市場規模・現状・予測（2021年-2027年） Ovarian cancer occurs and arises from several types of cells within the ovary, and it has the lowest survival rate of all gynecological cancers. Among many types, epithelial ovarian cancer (EOC) is the most common ovarian cancer, whereas ovarian low malignant potential tumor (OLMPT), germ cell tumor…